/PRNewswire/ Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, announces that it has signed a.
Theragnostics Strengthens Board of Directors with Key Appointments
Drug Development Experts Dr Dennis Langer and Professor Ken Herrmann Appointed as Non-Executive Directors
LONDON, Aug. 4, 2021 /PRNewswire/ Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, announces today the appointments of Dr Dennis Langer and Professor Ken Herrmann as Non-Executive Directors to its Board.
Dr Dennis Langer has served as a director of both public and private biotechnology, pharmaceutical and diagnostic companies, and has an extensive pharmaceutical company background. He previously served as CEO of Neose Technologies, Inc.; was President of Dr Reddy s North American business; and was Senior Vice President of Research and Development at GlaxoSmithKline plc. He is currently a Director of the Whitehead Institute for Biomedical Research, Myriad Genetics, Inc. (NASDAQ: MYGN) and Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX). Dr La
ABQ-IT Celebrates Official Ribbon Cutting with the Hispano Chamber of Commerce
IT Services Company Teams Up With Hispano Chamber to Help Protect Against Cybersecurity Threats
ALBUQUERQUE, NM / ACCESSWIRE / April 14, 2021 / On March 25, 2021, ABQ-IT celebrated its official ribbon cutting as a part of the Hispano Chamber of Commerce, complete with a red ribbon and giant scissors. The ceremony marked an offer from ABQ-IT for local businesses to receive a cybersecurity review and gain $250 towards their membership to the Chamber of Commerce.
To learn more about ABQ-IT and its services, visit www.abq-it.com.
Several ABQ-IT team members were present at the ribbon-cutting, sharing a bit of what ABQ-IT does and how they support local businesses. Co-founder and president Greg Mullen shared,
Share this article
Share this article
LONDON, Feb. 17, 2021 /PRNewswire/ Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, today announces a research collaboration with Essen University Hospital to examine Theragnostics investigational agent THG-008 for PET imaging in a range of cancers.
The research is due to start in February 2021 and will be led by Dr. Michael Nader, head of radiochemistry and part of the Clinic for Nuclear Medicine at Universitätsklinikum Essen (University Hospital Essen), in Germany.
THG-008 is a novel fluorine-18 radiolabelled PARP inhibitor (
18F-PARPi) which has a number of applications relevant to imaging cancer. A Phase 1 clinical study for THG-008 in head and neck squamous cell carcinoma (HNSCC) completed recruitment in May 2019. Data published in a peer-reviewed publication confirmed imaging of head and neck cancer with
By Lauren Petracca lpetracca@postandcourier.com
GOOSE CREEKÂ â Law enforcement in this fast-growing suburb is quietly undergoing a profound transformation, driven by a trailblazing top cop whose agenda has drawn both raves and resentment from the rank-and-file.
L.J. Roscoe, the Charleston regionâs first female and openly LGBTQ police chief, took the helm nearly two years ago with a mandate to reshape a police department that hadnât seen a new leader in three decades. And bring about change she has.
Under Roscoe, the Goose Creek Police Department has markedly expanded community policing, getting officers out of their cruisers and into neighborhoods to interact with residents. Sheâs helped build bridges between police and the cityâs growing minority populations. Sheâs boosted diversity in the department, improved officer training and updated police practices. During her first year on the job, violent crime tumbled more than 14 percent.